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254Objectives: We examined the characteristics and outcomes of patients requiring valve surgery during active
infective endocarditis (IE), focusing on the impact of antimicrobial therapy.
Methods: In this retrospective study, medical charts of all consecutive patients admitted to our cardiovascular
surgery department from January 1998 to December 2010, with a diagnosis of IE requiring surgical manage-
ment, were reviewed. Adult patients were enrolled in the study if they had definite or possible active IE and
if the antimicrobial treatment was evaluable.
Results: After initial screening of medical records, we selected 173 surgically treated patients (135 men; mean
age, 55.8 years). Nativevalveswere involved in 150 (87%) patients. IEmainly involved the aortic valve (n¼ 113)
and thenmitral (n¼ 83), tricuspid (n¼ 13), and pulmonary (n¼ 3) valves. Themost common causative pathogens
were streptococci (n¼ 70), staphylococci (n¼ 60), and enterococci (n¼ 29). Operativemortality was 15%.Mul-
tivariate logistic regression analysis demonstrated that adequacy of the overall antimicrobial treatment (adjusted
odds ratio, 0.292; 95% confidence interval, 0.117-0.726;P¼ .008) and temperature greater than 38C at the time
of diagnosis (adjusted odds ratio, 0.288; 95% confidence interval, 0.115-0.724; P ¼ .008) were independently
associated with a lower risk of mortality. Conversely, age greater than 60 years (adjusted odds ratio, 4.42;
95% confidence interval, 1.57-12.4; P ¼ .005) was associated with a greater risk of operative mortality.
Conclusions: Surgery for active IE is still associated with a high mortality rate, but its prognosis is significantly
improved by adequate antimicrobial therapy. (J Thorac Cardiovasc Surg 2014;147:254-8)The optimal management of infective endocarditis (IE)
requires a collaborative approach, notably involving spe-
cialists in microbiology, infectious diseases, cardiology,
cardiac surgery, and anaesthesiology.
Even if antimicrobial treatment represents the cornerstone
ofmanagement, recent data from the InternationalCollabora-
tiononEndocarditis—ProspectiveCohort Study1 have shown
that 1 (48%) of 2 patients required valve surgery. Periopera-
tive mortality varies between 5% and 36%.2-10 Prognosis
depends on the causative organism, the extent of destruction
of cardiac structures, the presence of complications of IE
such as heart failure, and the timing of surgery.11
Several studies have demonstrated that adequate antibi-
otic therapy improves the outcome of patients with severe
bacterial or fungal infection and that the involvement of
an infectious disease specialist could potentially increase
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The Journal of Thoracic and Cardiovascular SurgThe goal of the present study was to identify predictive
factors of mortality while focusing on the impact of antimi-
crobial therapy in a cohort of consecutive patients operated
on through a 13-year experience for active IE.PATIENTS AND METHODS
Study Design and Patients
A systematic retrospective review was carried out of all consecutive
patients admitted to the 2 units of the Cardiovascular Surgery Department
of Ho^pital Cardiologique de Lille, France, from January 1998 to December
2010, with a diagnosis of IE requiring surgical management. All medical
charts were analyzed by an independent group (Centre d’Investigation
Clinique, CHRU, Lille, France). In accordance with French law, no ethics
committee approval was required to conduct the study.
Adult patients were enrolled in the study if they had definite or possible
active IE and if the antimicrobial treatment of the episode of IE was evalu-
able. Definite or possible IE was defined according to modified Duke
criteria.16 Endocarditis was defined as active if the patient required surgery
before completion of a standard course of antibiotic treatment, irrespective
of whether there were ongoing signs of sepsis or whether blood and valve
cultures were positive for the infecting microorganism.2 Antimicrobial
treatment of the episode of IE was considered evaluable when the causative
organism(s), antibiotics used, and duration of postoperative antimicrobial
treatment were clearly identified. Patients with IE associated with pace-
maker implantation were excluded.
Data Collection and Definitions
Data were recorded on a standardized report form designed by 2 of the
authors (G.F., O.L.). Information about patient demographics, preexisting
conditions, focus of infection, initial valve status, clinical course, echocar-
diographic data, microbiologic data, complications, cardiac surgeryery c January 2014
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operative periods, and outcome were collected.
Prosthetic valve IE was defined as infection occurring on any type of
tissue or mechanical device. Hospital-acquired IE was defined as infection
occurring more than 72 hours after admission to the hospital or acquired in
association with a significant invasive procedure performed during a recent
hospitalization within 8 weeks of this hospitalization.17 Antimicrobial ther-
apy was considered as bacteriologically effective if it included antibiotic(s)
usually proposed by current guidelines (ie, amoxicillin or a third-
generation cephalosporin or a glycopeptide in the case of IE owing to Strep-
tococcus spp; amoxicillin or a glycopeptide for IE owing to Enterococcus
spp; oxacillin for IE owing to methicillin-susceptible Staphylococcus spp;
a glycopeptide for IE owing to methicillin-resistant Staphylococcus spp;
and a third-generation cephalosporin or fluoroquinolone for IE owing to
gram-negative bacilli) and if the causative organism was in vitro suscepti-
ble to at least 1 of the antibiotics of the regimen.18 The duration of postop-
erative antimicrobial treatment was considered correct when it was 2 weeks
or more when the leaflet culture was negative and 6 weeks when leaflet
culture was positive. The antimicrobial treatment was considered adequate
when it was bacteriologically effective in both the preoperative and postop-
erative periods and had a correct postoperative duration. Operative mortal-
ity was defined as death occurring within the same hospitalization as
surgery, regardless of its cause.2,3
Statistical Analysis
Descriptive analyses were performed to check and summarize the data.
Quantitative variables are reported as means  standard deviation. Quali-
tative variables are reported as number and percentage. Continuous
variables were compared using the Student t test. Categorical variables
were compared using the c2 test or Fisher’s exact test when c2 was not
appropriate.
A stepwise logistic regression analysis was performed including
variables with a P value  .10 in univariate analysis. Adjusted odds ratios
were computed using logistic regression analysis including the indepen-
dent predictors of mortality.
All statistical analyses were performed using SAS software, version 9.1
(SAS Institute, Inc, Cary, NC).
RESULTS
After initial screening of 371 medical records, we
excluded 140 patients who either had not had active IE or
did not meet modified Duke criteria for diagnosis, and we
retained 231 patients exhibiting definite or possible active
IE. Among them, the antimicrobial treatment of the episode
of IE was evaluable in 173 patients who met the eligibility
criteria for inclusion in this study.
Most patients had definite active IE (n ¼ 169; 98%).
Blood and leaflet cultures were positive in 168 (97%) and
23 (13%) cases, respectively. Echocardiography demon-
strated endocardial involvement in 163 (94%) cases.
Duke minor criteria observed were predisposition
(n ¼ 57), fever (n¼ 127), and vascular (n¼ 18) and immu-
nologic phenomena (n ¼ 7). IE was hospital acquired in 16
(9%) cases. Demographics characteristics, underlyingThe Journal of Thoracic and Cavalve diseases, and portal of entry are reported in Table 1.
Most patients (n ¼ 130; 75%) were referred from another
hospital.
Native and prosthetic valves were involved in 150 (87%)
and 23 (13%) patients, respectively. IE mainly involved the
aortic valve (n ¼ 113) and then mitral (n ¼ 83), tricuspid
(n ¼ 13), and pulmonary (n ¼ 3) valves. Multiple valve
involvement was observed in 38 (22%) patients. Valves
involved were aortic plus mitral valves (n ¼ 26), aortic
plus tricuspid valves (n ¼ 3), aortic plus pulmonary valves
(n ¼ 3), mitral plus tricuspid valves (n ¼ 5), and aortic plus
mitral plus tricuspid valves (n ¼ 1).
One hundred eighty-eight causative pathogens were iden-
tified. IE was polymicrobial in 13 patients. The most com-
mon were streptococci (n ¼ 70; 37%), staphylococci
(n¼ 60; 31.5%), and enterococci (n¼ 29; 15.5%) (Table 2).
During the course of IE and before the surgical proce-
dure, 84 (49%) patients exhibited extracardiac involve-
ment. Main organs involved were central nervous system
(n ¼ 49), spleen (n ¼ 3 4), lung (n ¼ 13), bone and joints
(n ¼ 13), kidneys (n ¼ 10), and liver (n ¼ 3).
Surgery was performed in the acute phase of IE with
a mean delay from diagnosis to surgery of 22.9  17.5
days. Main indications for surgery were 1 or more of the fol-
lowing reasons: persistent infection despite 7 to 10 days of
bacteriologically effective antibiotic treatment (n ¼ 100),
vegetation size (n ¼ 50), congestive heart failure
(n ¼ 60), recurrent embolization (n ¼ 22), annular abscess
(n ¼ 21), and conduction abnormalities (n ¼ 5). A total of
86 bioprostheses, 63 mechanical prostheses, and 9 aortic
homografts were implanted. After excision of the vegeta-
tions, valve repair was performed alone (n¼ 15) or in asso-
ciation with prosthesis implantation (n ¼ 7) in 22 cases.
After the surgical procedure, all patients were admitted to
the surgical intensive care unit (ICU). Vasopressors and/or
inotropes were required in 99 (57%) cases. Renal replace-
ment therapy was required in 19 cases. The mean duration
of postoperative mechanical ventilation was 55.8  96.4
hours. The mean duration of ICU stay was 150 152 hours.
All patients received a preoperative antimicrobial treat-
ment. Its mean duration before surgery was 21.4  14.5
days. This antimicrobial treatment was bacteriologically ef-
fective in 159 (92%) patients. In 7 patients, antibiotics used
were not usually proposed by current guidelines. In the
remaining 7 patients, at least 1 causative pathogen was re-
sistant to all antibiotics of the regimen. In 1 case, this point
was explained by a late postoperative identification of caus-
ative pathogen. Blood cultures were negative whereas leaf-
let culture identified a pathogen resistant to the preoperative
antibiotic regimen. Postoperative antimicrobial treatment
was bacteriologically effective in 163 (94%) cases. In 10
patients, either antibiotics used were not usually proposed
by current guidelines (n ¼ 5) or at least 1 causative patho-
gen was resistant to all antibiotics of the regimen (n ¼ 5).rdiovascular Surgery c Volume 147, Number 1 255
TABLE 1. Demographic characteristics of the study population
(n ¼ 173)
Characteristic n (%) or mean (±SD)
Men 135 (78)
Age (y) 55.8  15.9
Underlying valve diseases 53 (31)
Mitral insufficiency 9
Aortic insufficiency 12
Aortic stenosis 7
Valve prosthesis 23
Other 2
History of IE 4 (2)
Identified portal of entry 87 (50)
Dental or upper respiratory tract 40 (23)
Cutaneous 17 (10)
Digestive tract 14 (8)
Intravenous drug use 4 (2)
Cardiovascular procedure or vascular access 10 (6)
Genitourinary tract 4 (2)
SD, Standard deviation; IE, infective endocarditis.
TABLE 3. Bivariate analysis of risk factors for operative mortality
Factor
Survivors
(n ¼ 147)
Nonsurvivors
(n ¼ 26)
P
value
Male gender 117 18 .3
Mean age (y) 54.0  16.3 65.7  9.4 <.0001
Age>60 y 67 20 .003
Temperature>38C at the time
of diagnosis
114 13 .006
Aortic IE 98 15 .38
Mitral IE 69 14 .53
Multiple valve IE 34 4 .53
Prosthetic valve endocarditis 16 7 .05
Staphylococcal IE 48 9 .84
Streptococcal IE 86 13 .42
Gram-negative bacilli IE 15 3 .74
Fungal IE 2 2 .1
Polymicrobial IE 11 2 1
Hospital-acquired IE 14 2 1
Periannular complications 28 7 .36
Vegetations>15 mm 39 5 .43
Neurologic complications 41 8 .76
Extracardiac involvement 72 12 .95
Preoperative antimicrobial
treatment bacteriologically
effective
140 19 .001
Postoperative antimicrobial
treatment bacteriologically
effective
139 24 .65
Correct duration of postoperative
antimicrobial treatment
119 16 .04
Adequacy of the overall
antimicrobial treatment
110 12 .003
IE, Infective endocarditis.
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correct in 135 (78%) cases. In 38 cases, treatment was
stopped too early. Finally, the overall antimicrobial treat-
ment was considered adequate in 122 (70.5%) patients.
During hospitalization, 26 (15%) patients died. Bivariate
analysis of main risk factors for operative mortality is
reported in Table 3. Nonsurvivors were significantly older
(65.7  9.4 vs 54.0  16.3 years) and the mortality rate
was significantly higher when temperature was less than
38Cat the time of diagnosis (28.3% vs 10.2%), IE involved
a prosthetic valve (30.5% vs 12.7%), preoperative antimi-
crobial treatment was not bacteriologically effective (50%
vs 12%), duration of postoperative antimicrobial treatment
was not correct (26.3% vs 11.8%), and overall antimicro-
bial treatment was not adequate (27.5% vs 9.8%).
The results ofmultivariate analysis are reported in Table 4.
Age older than 60 years, temperature greater than 38C at the
time of diagnosis, and adequacy of the overall antimicrobialTABLE 2. Causative microorganisms (n ¼ 188) isolated from cases of
active IE
Micro organism n (%)
Streptococcus spp 70 (37)
Enterococcus spp 29 (15.5)
Staphylococcus aureus 40 (21)
Methicillin-susceptible 35
Methicillin-resistant 5
Coagulase-negative Staphylococcus 20 (10.5)
Gram-negative bacilli 20 (10.5)
Haemophilus influenzae 6
Other 14
Gram-positive bacilli 5 (2.5)
Candida spp 3 (1.5)
Aspergillus spp 1 (0.5)
IE, Infective endocarditis; spp, species.
256 The Journal of Thoracic and Cardiovascular Surgtreatment are the independent predictors of operative mortal-
ity. The first is associated with an increased mortality,
whereas the others are associated with an increased survival.DISCUSSION
This study underlines the high mortality rate associated
with surgery during the active phase of IE and demonstrates
that an adequate antimicrobial treatment associated with
surgery is an independent factor improving the outcome.
The recent European guideline on the prevention, diagno-
sis, and treatment of IE emphasizes the high in-hospitalTABLE 4. Multivariate analysis for independent predictors for
operative mortality
Parameter AOR 95% CI P value
Age>60 y 3.71 1.35-10.20 .01
Temperature>38C at the time
of diagnosis
0.29 0.12-0.73 .008
Adequacy of the overall
antimicrobial treatment
0.34 0.14-0.84 .02
AOR, Adjusted odds ratio; CI, confidence interval.
ery c January 2014
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26%.18 The outcome is influenced by patient characteristics
(ie, age, comorbidities, prosthetic valve, and diabetes melli-
tus), the occurrence of cardiac and noncardiac complica-
tions (ie, heart or renal failure, septic shock, stroke), the
causative organism (S aureus, gram-negative bacilli,
fungus), and echocardiographic findings (ie, periannular
complications, large vegetations, pulmonary hypertension,
severe left-sided valve regurgitation). Numerous studies
have examined the outcome of patients’ need for surgery
during the active phase of IE. In-hospital mortality rate
varies from 5.7% to 36%.2-10 Although identified
prognostic factors differ from 1 study to another, it
appears that outcome could be improved by early surgery
and is impaired by the presence of the following factors:
low left ventricular ejection fraction, severe congestive
heart failure, pulmonary edema, preoperative shock, septic
shock, prosthetic valve endocarditis, paravalvular abscess,
infection owing to Staphylococcus spp or S aureus, large
(>15 mm) vegetations, emergency surgery, persistent
infection, and renal failure.3,4,6-11
To the best of our knowledge, the role of antimicrobial
therapy and the impact of its adequacy on prognosis of IE
have never been clearly studied, and no study has specifi-
cally focused on the prognostic impact of antimicrobial
treatment associated with surgery during the active phase
of IE. As demonstrated by Kollef,12 Ibrahim,13 and their
coworkers more than 10 years ago, an inadequate antimi-
crobial therapy impaired the prognosis of critically ill
patients and of those with bloodstream infections. In
a previous study, including 108 patients requiring surgery
during active IE for which the adequacy of antimicrobial
treatment was evaluable, we19 found a 3-fold higher mortal-
ity rate (25.8% vs 9%) when antimicrobial treatment was
inadequate. In the present work, we found similar results
inasmuch as operative mortality was 9.8%when antimicro-
bial treatment was adequate and 27.5% when it was not.
Moreover, the adequacy of antimicrobial treatment
associated with surgery appears as an independent prognos-
tic factor in multivariate analysis. This result highlights the
role of the infectious disease specialist collaboration with
cardiologists, cardiac surgeons, and anesthesiologists as
a multidisciplinary team.
The results of our prognostic analysis require further com-
ments. As previously reported, the causative organism could
influence prognosis, and it is currently admitted that staphy-
lococcal IE has a worse outcome than IE owing to other
organisms.However, in our series,mortality rates are similar
in staphylococcal IE (15.8%) and in IE owing to other
organisms (14.7%). Similarly, large (>15 mm) vegetations
have no prognostic impact in our series. Prosthetic IE is
associated in our series, as in numerous others, with a higher
mortality rate (30.5% vs 12.7%). Nevertheless, it does not
appear as a significant independent prognostic factor,The Journal of Thoracic and Caprobably because of a too-low sample size (n ¼ 23). There
is no clear explanation about other discrepancies between
our results and those reported in the literature. We could
simply remark that results of previous studies2-10 are
heterogeneous and that such differences are often
observed. The last point discussed is about the prognostic
impact of temperature greater than 38C at the time of
diagnosis that appears as an independent factor improving
the outcome. This criterion is 1 of the minor modified
Duke criteria for the diagnosis of IE. It was systematically
collected in our database and, so, was included in our
prognostic analysis. Such a result could appear surprising
and be considered as a false result owing to a bias of the
statistical analysis. However, recent data about association
between fever and outcome of severely ill patients with
infection suggest that our result could be plausible. Young
and coworkers20 demonstrated that an elevated peak temper-
ature in the first 24 hours in the ICU was associated with
decreased in-hospitalmortality.Although there is no definite
explanation to their results, the authors remembered that
fever causes direct inhibition of a number of bacteria and
increases in vitro antibiotic activity.
This study had several limitations. First, our study is based
on a retrospective monocentric analysis of the medical
charts of all consecutive patients admitted to the Cardiovas-
cular Surgery Department of Ho^pital Cardiologique de Lille
for surgical management of suspected IE. Data were retro-
spectively collected by an independent group on a standard-
ized report. These points associated with stringent inclusion
criteria led to exclusion from the cohort of 371 patients who
underwent surgery during the study period, 140 patients for
whom the diagnosis of definite or possible and active IE was
not retained, and 58 patients for whom the antimicrobial
treatment was not evaluable. Similarly, parameters such as
evaluation of left ventricular function, exact timing of the
surgical procedure, and precise echocardiographic findings
were sometimes lacking, leading to exclusion of some of
them from the prognostic analysis. Third, the definition of
the adequacy of antimicrobial treatment could appear insuf-
ficiently precise since based only on the duration of treat-
ment and the antibiotic(s) used comparatively to current
guidelines. However, in most studies, an inadequate treat-
ment is only defined as microbiologic documentation of an
infection that is not being effectively treated.21 Finally, there
is no long-term follow-up. However, inasmuch asmost stud-
ies on the prognostic impact of antimicrobial treatment dem-
onstrated a relationship between adequacy and hospital
mortality,12,13 we chose to focus on operative mortality.
In conclusion, the in-hospital outcome of patients under-
going valve surgery during active IE was impaired when
infection occurred in patients aged more than 60 years.
Conversely, temperature greater than 38C at the time of di-
agnosis and adequacy of the overall antimicrobial treatment
have improved the prognosis.rdiovascular Surgery c Volume 147, Number 1 257
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